Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

OBJECTIVE: Assessing safety and immunogenicity of an inactivated whole virus particle vaccine. DESIGN: Single-centre, double-blind, randomised, placebo-controlled, phase I (stage I: 18–50, stage II: 51–75 years), phase II (18–75 years) clinical trials. SETTING: 29 December 2020 to 22 April 2021. PAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohraz, Minoo, Salehi, Mohammadreza, Tabarsi, Payam, Abbasi-Kangevari, Mohsen, Ghamari, Seyyed-Hadi, Ghasemi, Erfan, Amini Pouya, Maryam, Rezaei, Negar, Ahmadi, Naser, Heidari, Kazem, Malekpour, Mohammad-Reza, Nasiri, Mojtaba, Amirzargar, Ali Akbar, Saeedi Moghaddam, Sahar, Larijani, Bagher, Hosseini, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Global Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995575/
https://www.ncbi.nlm.nih.gov/pubmed/35396297
http://dx.doi.org/10.1136/bmjopen-2021-056872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995575/
https://www.ncbi.nlm.nih.gov/pubmed/35396297
http://dx.doi.org/10.1136/bmjopen-2021-056872

Ejemplares similares